Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on AC Immune SA and keeping the price target at $12.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Andrew Fein has given his Buy rating due to a combination of factors including the promising potential of AC Immune SA’s vaccine platform, particularly with the upcoming data readout for ACI-7104 in Parkinson’s disease. The focus is on three critical elements: target engagement, clinical signal, and safety. Previous results have demonstrated significant reductions in oligomeric α-synuclein levels, which are considered clinically meaningful, and the upcoming data will further assess these effects in a larger patient cohort.
Fein believes that even a directional correlation between α-synuclein lowering and motor function improvements could be a significant indicator for the field. Additionally, the clean safety and tolerability profile of the vaccine is crucial, given the challenges faced by antibody approaches. If ACI-7104 can achieve these outcomes, it could validate the active immunization approach in neurodegeneration, potentially extending the platform’s credibility beyond Alzheimer’s and tau, and supporting the broader thesis that vaccines could become a key component in treating neurodegenerative diseases.
According to TipRanks, Fein is a 5-star analyst with an average return of 24.9% and a 52.49% success rate. Fein covers the Healthcare sector, focusing on stocks such as Alector, Liquidia Technologies, and BioCryst.